Alliancebernstein L.P. Sells 66,120 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Alliancebernstein L.P. decreased its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 64.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 36,010 shares of the specialty pharmaceutical company’s stock after selling 66,120 shares during the period. Alliancebernstein L.P. owned 0.11% of Collegium Pharmaceutical worth $1,032,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. New Age Alpha Advisors LLC bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at $40,000. KBC Group NV boosted its position in shares of Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after acquiring an additional 982 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after acquiring an additional 316 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Collegium Pharmaceutical by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after acquiring an additional 642 shares during the last quarter. Finally, Aigen Investment Management LP purchased a new stake in shares of Collegium Pharmaceutical in the fourth quarter worth about $230,000.

Analyst Ratings Changes

Several equities analysts have weighed in on COLL shares. Piper Sandler cut their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. StockNews.com downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Saturday. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research report on Wednesday, April 9th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Trading Down 0.0 %

COLL opened at $27.01 on Friday. The stock’s 50 day moving average price is $28.74 and its 200-day moving average price is $31.24. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a one year low of $23.23 and a one year high of $42.29. The stock has a market cap of $867.89 million, a price-to-earnings ratio of 11.64 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. On average, equities analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, CFO Colleen Tupper sold 10,445 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $30.01, for a total transaction of $313,454.45. Following the transaction, the chief financial officer now owns 165,246 shares in the company, valued at $4,959,032.46. This represents a 5.95 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the sale, the executive vice president now directly owns 154,204 shares in the company, valued at approximately $4,330,048.32. This represents a 20.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 81,693 shares of company stock worth $2,334,994 over the last three months. Corporate insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.